> top > docs > PMC:3342329 > spans > 26255-26766 > annotations

PMC:3342329 / 26255-26766 JSONTXT

Annnotations TAB JSON ListView MergeView

test3

Id Subject Object Predicate Lexical cue
T9001 498-502 Protein denotes CCR5
T9000 479-485 Protein denotes IL-1Ra
T8999 321-325 Protein denotes CCR5
T8998 175-179 Protein denotes CCR5
T8997 161-171 Negative_regulation denotes inhibition
T8996 70-74 Protein denotes CCR5
T8995 56-60 Protein denotes CCR5
T8909 498-502 Protein denotes CCR5
T8908 479-485 Protein denotes IL-1Ra
T8907 321-325 Protein denotes CCR5
T8906 175-179 Protein denotes CCR5
T8905 70-74 Protein denotes CCR5
T8904 56-60 Protein denotes CCR5
R5918 T8998 T8997 themeOf CCR5,inhibition

testone

Id Subject Object Predicate Lexical cue
T8816 498-502 Protein denotes CCR5
T8815 479-485 Protein denotes IL-1Ra
T8814 321-325 Protein denotes CCR5
T8813 175-179 Protein denotes CCR5
T8812 70-74 Protein denotes CCR5
T8811 56-60 Protein denotes CCR5

BioNLP16_Messiy

Id Subject Object Predicate Lexical cue
T11196 161-171 Negative_regulation denotes inhibition
T11171 498-502 Protein denotes CCR5
T11170 479-485 Protein denotes IL-1Ra
T11169 321-325 Protein denotes CCR5
T11168 175-179 Protein denotes CCR5
T11167 70-74 Protein denotes CCR5
T11166 56-60 Protein denotes CCR5
R7418 T11168 T11196 themeOf CCR5,inhibition

BioNLP16_DUT

Id Subject Object Predicate Lexical cue
T10842 479-485 Protein denotes IL-1Ra
T10841 321-325 Protein denotes CCR5
T10840 175-179 Protein denotes CCR5
T10839 70-74 Protein denotes CCR5
T10838 56-60 Protein denotes CCR5
T10870 161-171 Negative_regulation denotes inhibition
T10843 498-502 Protein denotes CCR5
R7326 T10840 T10870 themeOf CCR5,inhibition

2_test

Id Subject Object Predicate Lexical cue
22567084-12788340-91707059 299-301 12788340 denotes 53

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T10734 506-510 NN denotes mice
T10733 498-505 NN denotes CCR5−/−
T10732 495-497 IN denotes in
T10731 486-494 NN denotes pathways
T10730 473-485 NN denotes NF-κB/IL-1Ra
T10729 470-472 IN denotes of
T10728 459-469 NN denotes modulation
T10727 455-458 IN denotes via
T10726 445-454 VB denotes inhibited
T10725 441-444 VB denotes was
T10724 434-440 NN denotes growth
T10723 428-433 NN denotes cells
T10722 419-427 NN denotes melanoma
T10721 414-418 IN denotes that
T10720 407-413 VB denotes showed
T10719 401-406 NN denotes study
T10718 396-400 DT denotes this
T10717 394-395 -COMMA- denotes ,
T10716 387-394 NN denotes summary
T10715 384-386 IN denotes In
T10714 369-382 NN denotes investigation
T10713 359-368 JJ denotes continued
T10712 350-358 VB denotes warrants
T10711 345-349 WDT denotes that
T10710 338-344 NN denotes target
T10709 331-337 NN denotes cancer
T10708 329-330 DT denotes a
T10707 326-328 VB denotes is
T10706 321-325 NN denotes CCR5
T10705 313-320 VB denotes believe
T10704 310-312 PRP denotes we
T10703 308-309 -COMMA- denotes ,
T10702 304-308 RB denotes Thus
T10701 301-302 -RRB- denotes ]
T10700 299-301 CD denotes 53
T10699 298-299 -LRB- denotes [
T10698 294-297 NN denotes HIV
T10697 291-293 IN denotes as
T10696 286-290 JJ denotes such
T10695 277-285 NN denotes diseases
T10694 269-276 JJ denotes certain
T10693 266-268 IN denotes in
T10692 262-265 NN denotes use
T10691 258-261 IN denotes for
T10690 251-257 NN denotes trials
T10689 242-250 JJ denotes clinical
T10688 239-241 IN denotes in
T10687 234-238 JJ denotes safe
T10686 231-233 VB denotes be
T10685 228-230 TO denotes to
T10684 222-227 VB denotes shown
T10683 217-221 VB denotes been
T10682 209-216 RB denotes already
T10681 204-208 VB denotes have
T10680 194-203 NN denotes compounds
T10679 189-193 JJ denotes such
T10678 181-188 JJ denotes Several
T10677 175-179 NN denotes CCR5
T10676 172-174 IN denotes of
T10675 161-171 NN denotes inhibition
T10674 157-160 DT denotes the
T10673 153-156 IN denotes for
T10672 144-152 NN denotes molecule
T10671 138-143 JJ denotes small
T10670 136-137 DT denotes a
T10669 133-135 IN denotes as
T10668 129-132 VB denotes use
T10667 126-128 TO denotes to
T10666 117-125 JJ denotes amenable
T10665 114-116 VB denotes is
T10664 111-113 PRP denotes it
T10663 107-110 CC denotes and
T10662 98-106 NN denotes receptor
T10661 82-97 VB denotes protein–coupled
T10660 80-81 NN denotes G
T10659 78-79 DT denotes a
T10658 75-77 VB denotes is
T10657 70-74 NN denotes CCR5
T10656 62-69 IN denotes because
T10655 60-61 -COMMA- denotes ,
T10654 56-60 NN denotes CCR5
T10653 53-55 IN denotes of
T10652 40-52 NN denotes implications
T10651 31-39 JJ denotes clinical
T10650 19-30 JJ denotes significant
T10649 14-18 VB denotes show
T10648 9-13 RB denotes thus
T10647 4-8 NN denotes data
T10646 0-3 PRP-DOLLAR- denotes Our
R7212 T10647 T10646 arg1Of data,Our
R7213 T10647 T10649 arg1Of data,show
R7214 T10649 T10648 arg1Of show,thus
R7215 T10649 T10655 arg1Of show,","
R7216 T10649 T10656 arg1Of show,because
R7217 T10651 T10650 arg1Of clinical,significant
R7218 T10652 T10649 arg2Of implications,show
R7219 T10652 T10651 arg1Of implications,clinical
R7220 T10652 T10653 arg1Of implications,of
R7221 T10654 T10653 arg2Of CCR5,of
R7222 T10657 T10658 arg1Of CCR5,is
R7223 T10658 T10663 arg1Of is,and
R7224 T10661 T10660 arg1Of protein–coupled,G
R7225 T10662 T10658 arg2Of receptor,is
R7226 T10662 T10659 arg1Of receptor,a
R7227 T10662 T10661 arg1Of receptor,protein–coupled
R7228 T10663 T10656 arg2Of and,because
R7229 T10664 T10665 arg1Of it,is
R7230 T10664 T10666 arg1Of it,amenable
R7231 T10664 T10668 arg2Of it,use
R7232 T10665 T10663 arg2Of is,and
R7233 T10666 T10665 arg2Of amenable,is
R7234 T10668 T10666 arg2Of use,amenable
R7235 T10668 T10667 arg1Of use,to
R7236 T10668 T10669 arg1Of use,as
R7237 T10672 T10669 arg2Of molecule,as
R7238 T10672 T10670 arg1Of molecule,a
R7239 T10672 T10671 arg1Of molecule,small
R7240 T10672 T10673 arg1Of molecule,for
R7241 T10675 T10673 arg2Of inhibition,for
R7242 T10675 T10674 arg1Of inhibition,the
R7243 T10675 T10676 arg1Of inhibition,of
R7244 T10677 T10676 arg2Of CCR5,of
R7245 T10680 T10678 arg1Of compounds,Several
R7246 T10680 T10679 arg1Of compounds,such
R7247 T10680 T10681 arg1Of compounds,have
R7248 T10680 T10683 arg1Of compounds,been
R7249 T10680 T10684 arg2Of compounds,shown
R7250 T10680 T10686 arg1Of compounds,be
R7251 T10680 T10687 arg1Of compounds,safe
R7252 T10684 T10681 arg2Of shown,have
R7253 T10684 T10682 arg1Of shown,already
R7254 T10684 T10683 arg2Of shown,been
R7255 T10686 T10684 arg3Of be,shown
R7256 T10686 T10685 arg1Of be,to
R7257 T10687 T10686 arg2Of safe,be
R7258 T10687 T10688 arg1Of safe,in
R7259 T10690 T10688 arg2Of trials,in
R7260 T10690 T10689 arg1Of trials,clinical
R7261 T10690 T10691 arg1Of trials,for
R7262 T10692 T10691 arg2Of use,for
R7263 T10692 T10693 arg1Of use,in
R7264 T10695 T10693 arg2Of diseases,in
R7265 T10695 T10694 arg1Of diseases,certain
R7266 T10695 T10697 arg1Of diseases,as
R7267 T10697 T10696 arg1Of as,such
R7268 T10698 T10697 arg2Of HIV,as
R7269 T10698 T10699 arg1Of HIV,[
R7270 T10700 T10699 arg2Of 53,[
R7271 T10701 T10699 arg3Of ],[
R7272 T10704 T10705 arg1Of we,believe
R7273 T10705 T10702 arg1Of believe,Thus
R7274 T10705 T10703 arg1Of believe,","
R7275 T10706 T10707 arg1Of CCR5,is
R7276 T10707 T10705 arg2Of is,believe
R7277 T10710 T10707 arg2Of target,is
R7278 T10710 T10708 arg1Of target,a
R7279 T10710 T10709 arg1Of target,cancer
R7280 T10710 T10711 arg1Of target,that
R7281 T10710 T10712 arg1Of target,warrants
R7282 T10714 T10712 arg2Of investigation,warrants
R7283 T10714 T10713 arg1Of investigation,continued
R7284 T10716 T10715 arg2Of summary,In
R7285 T10719 T10718 arg1Of study,this
R7286 T10719 T10720 arg1Of study,showed
R7287 T10720 T10715 arg1Of showed,In
R7288 T10720 T10717 arg1Of showed,","
R7289 T10724 T10722 arg1Of growth,melanoma
R7290 T10724 T10723 arg1Of growth,cells
R7291 T10724 T10725 arg1Of growth,was
R7292 T10724 T10726 arg2Of growth,inhibited
R7293 T10726 T10720 arg2Of inhibited,showed
R7294 T10726 T10721 arg1Of inhibited,that
R7295 T10726 T10725 arg2Of inhibited,was
R7296 T10726 T10727 arg1Of inhibited,via
R7297 T10728 T10727 arg2Of modulation,via
R7298 T10728 T10729 arg1Of modulation,of
R7299 T10731 T10729 arg2Of pathways,of
R7300 T10731 T10730 arg1Of pathways,NF-κB/IL-1Ra
R7301 T10731 T10732 arg1Of pathways,in
R7302 T10734 T10732 arg2Of mice,in
R7303 T10734 T10733 arg1Of mice,CCR5−/−

bionlp-st-ge-2016-test-proteins

Id Subject Object Predicate Lexical cue
T9218 498-502 Protein denotes CCR5
T9217 479-485 Protein denotes IL-1Ra
T9216 321-325 Protein denotes CCR5
T9215 175-179 Protein denotes CCR5
T9214 70-74 Protein denotes CCR5
T9213 56-60 Protein denotes CCR5

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T10918 479-485 http://www.uniprot.org/uniprot/P18510 denotes IL-1Ra
T10902 498-502 http://www.uniprot.org/uniprot/P51681 denotes CCR5
T10901 321-325 http://www.uniprot.org/uniprot/P51681 denotes CCR5
T10900 175-179 http://www.uniprot.org/uniprot/P51681 denotes CCR5
T10899 70-74 http://www.uniprot.org/uniprot/P51681 denotes CCR5
T10898 56-60 http://www.uniprot.org/uniprot/P51681 denotes CCR5

GO-BP

Id Subject Object Predicate Lexical cue
T9243 428-440 http://purl.obolibrary.org/obo/GO_0016049 denotes cells growth
T9234 434-440 http://purl.obolibrary.org/obo/GO_0040007 denotes growth

GO-CC

Id Subject Object Predicate Lexical cue
T9309 428-433 http://purl.obolibrary.org/obo/GO_0005623 denotes cells

sentences

Id Subject Object Predicate Lexical cue
T9058 384-511 Sentence denotes In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice.
T9057 304-383 Sentence denotes Thus, we believe CCR5 is a cancer target that warrants continued investigation.
T9056 181-303 Sentence denotes Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53].
T9055 0-180 Sentence denotes Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5.
T197 0-180 Sentence denotes Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein–coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5.
T198 181-303 Sentence denotes Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53].
T199 304-383 Sentence denotes Thus, we believe CCR5 is a cancer target that warrants continued investigation.
T200 384-511 Sentence denotes In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-κB/IL-1Ra pathways in CCR5−/− mice.

simple1

Id Subject Object Predicate Lexical cue
T9411 498-502 Protein denotes CCR5
T9410 479-485 Protein denotes IL-1Ra
T9409 321-325 Protein denotes CCR5
T9408 175-179 Protein denotes CCR5
T9407 70-74 Protein denotes CCR5
T9406 56-60 Protein denotes CCR5

DLUT931

Id Subject Object Predicate Lexical cue
T11032 161-171 Negative_regulation denotes inhibition
T11000 498-502 Protein denotes CCR5
T10999 479-485 Protein denotes IL-1Ra
T10998 321-325 Protein denotes CCR5
T10997 175-179 Protein denotes CCR5
T10996 70-74 Protein denotes CCR5
T10995 56-60 Protein denotes CCR5
R7369 T10997 T11032 themeOf CCR5,inhibition

bionlp-st-ge-2016-test-ihmc

Id Subject Object Predicate Lexical cue
T11678 157-179 Negative_regulation denotes the inhibition of CCR5
T11648 53-60 Protein denotes of CCR5
T11633 70-74 Protein denotes CCR5
T11599 506-510 Protein denotes mice
T11572 136-179 Entity denotes a small molecule for the inhibition of CCR5
T11561 321-325 Protein denotes CCR5
T11556 78-106 Protein denotes a G protein–coupled receptor
T11548 470-494 Protein denotes of NF-κB/IL-1Ra pathways
T11514 479-485 Protein denotes IL-1Ra
T11508 172-179 Protein denotes of CCR5
T11498 419-440 Entity denotes melanoma cells growth
R7553 T11508 T11678 themeOf of CCR5,the inhibition of CCR5

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T13143 510-511 . denotes .
T13142 506-510 NNS denotes mice
T13141 504-505 NN denotes −
T13140 503-504 NN denotes /
T13139 502-503 CD denotes −
T13138 498-502 CD denotes CCR5
T13137 495-497 IN denotes in
T13136 486-494 NNS denotes pathways
T13135 479-485 NNP denotes IL-1Ra
T13134 478-479 NNP denotes /
T13133 473-478 NNP denotes NF-κB
T13132 470-472 IN denotes of
T13131 459-469 NN denotes modulation
T13130 455-458 IN denotes via
T13129 445-454 VBN denotes inhibited
T13128 441-444 VBD denotes was
T13127 434-440 NN denotes growth
T13126 428-433 NNS denotes cells
T13125 419-427 NN denotes melanoma
T13124 414-418 IN denotes that
T13123 407-413 VBD denotes showed
T13122 401-406 NN denotes study
T13121 396-400 DT denotes this
T13120 394-395 , denotes ,
T13119 387-394 NN denotes summary
T13118 384-386 IN denotes In
T13117 382-383 . denotes .
T13116 369-382 NN denotes investigation
T13115 359-368 VBN denotes continued
T13114 350-358 VBZ denotes warrants
T13113 345-349 WDT denotes that
T13112 338-344 NN denotes target
T13111 331-337 NN denotes cancer
T13110 329-330 DT denotes a
T13109 326-328 VBZ denotes is
T13108 321-325 NNP denotes CCR5
T13107 313-320 VBP denotes believe
T13106 310-312 PRP denotes we
T13105 308-309 , denotes ,
T13104 304-308 RB denotes Thus
T13103 302-303 . denotes .
T13102 301-302 NNP denotes ]
T13101 299-301 CD denotes 53
T13100 298-299 NNP denotes [
T13099 294-297 NNP denotes HIV
T13098 291-293 IN denotes as
T13097 286-290 JJ denotes such
T13096 277-285 NNS denotes diseases
T13095 269-276 JJ denotes certain
T13094 266-268 IN denotes in
T13093 262-265 NN denotes use
T13092 258-261 IN denotes for
T13091 251-257 NNS denotes trials
T13090 242-250 JJ denotes clinical
T13089 239-241 IN denotes in
T13088 234-238 JJ denotes safe
T13087 231-233 VB denotes be
T13086 228-230 TO denotes to
T13085 222-227 VBN denotes shown
T13084 217-221 VBN denotes been
T13083 209-216 RB denotes already
T13082 204-208 VBP denotes have
T13081 194-203 NNS denotes compounds
T13080 189-193 JJ denotes such
T13079 181-188 JJ denotes Several
T13078 179-180 . denotes .
T13077 175-179 NNP denotes CCR5
T13076 172-174 IN denotes of
T13075 161-171 NN denotes inhibition
T13074 157-160 DT denotes the
T13073 153-156 IN denotes for
T13072 144-152 NN denotes molecule
T13071 138-143 JJ denotes small
T13070 136-137 DT denotes a
T13069 133-135 IN denotes as
T13068 129-132 VB denotes use
T13067 126-128 TO denotes to
T13066 117-125 JJ denotes amenable
T13065 114-116 VBZ denotes is
T13064 111-113 PRP denotes it
T13063 107-110 CC denotes and
T13062 98-106 NN denotes receptor
T13061 90-97 VBN denotes coupled
T13060 82-89 NN denotes protein
T13059 80-81 NNP denotes G
T13058 78-79 DT denotes a
T13057 75-77 VBZ denotes is
T13056 70-74 NNP denotes CCR5
T13055 62-69 IN denotes because
T13054 60-61 , denotes ,
T13053 56-60 NNP denotes CCR5
T13052 53-55 IN denotes of
T13051 40-52 NNS denotes implications
T13050 31-39 JJ denotes clinical
T13049 19-30 JJ denotes significant
T13048 14-18 VBP denotes show
T13047 9-13 RB denotes thus
T13046 4-8 NNS denotes data
T13045 0-3 PRP$ denotes Our
R8897 T13085 T13085 ROOT shown,shown
R8898 T13086 T13087 aux to,be
R8900 T13087 T13085 xcomp be,shown
R8901 T13088 T13087 acomp safe,be
R8902 T13089 T13088 prep in,safe
R8904 T13090 T13091 amod clinical,trials
R8905 T13091 T13089 pobj trials,in
R8907 T13092 T13087 prep for,be
R8908 T13093 T13092 pobj use,for
R8909 T13094 T13093 prep in,use
R8911 T13095 T13096 amod certain,diseases
R8912 T13096 T13094 pobj diseases,in
R8913 T13097 T13098 amod such,as
R8915 T13098 T13096 prep as,diseases
R8916 T13099 T13100 compound HIV,[
R8918 T13100 T13098 pobj [,as
R8919 T13101 T13102 nummod 53,]
R8920 T13102 T13100 conj ],[
R8922 T13103 T13085 punct .,shown
R8923 T13104 T13107 advmod Thus,believe
R8924 T13105 T13107 punct ",",believe
R8926 T13106 T13107 nsubj we,believe
R8927 T13107 T13107 ROOT believe,believe
R8928 T13108 T13109 nsubj CCR5,is
R8930 T13109 T13107 ccomp is,believe
R8931 T13110 T13112 det a,target
R8932 T13111 T13112 compound cancer,target
R8933 T13112 T13109 attr target,is
R8935 T13113 T13116 dobj that,investigation
R8936 T13114 T13115 nsubj warrants,continued
R8939 T13115 T13116 amod continued,investigation
R8943 T13116 T13112 appos investigation,target
R8944 T13117 T13107 punct .,believe
R8945 T13118 T13123 prep In,showed
R8946 T13119 T13118 pobj summary,In
R8947 T13120 T13123 punct ",",showed
R8949 T13121 T13122 det this,study
R8950 T13122 T13123 nsubj study,showed
R8951 T13123 T13123 ROOT showed,showed
R8952 T13124 T13129 mark that,inhibited
R8954 T13125 T13126 compound melanoma,cells
R8955 T13126 T13127 compound cells,growth
R8957 T13127 T13129 nsubjpass growth,inhibited
R8958 T13128 T13129 auxpass was,inhibited
R8960 T13129 T13123 ccomp inhibited,showed
R8961 T13130 T13129 prep via,inhibited
R8962 T13131 T13130 pobj modulation,via
R8964 T13132 T13131 prep of,modulation
R8965 T13133 T13135 compound NF-κB,IL-1Ra
R8966 T13134 T13135 compound /,IL-1Ra
R8968 T13135 T13136 compound IL-1Ra,pathways
R8969 T13136 T13132 pobj pathways,of
R8970 T13137 T13129 prep in,inhibited
R8972 T13138 T13142 nummod CCR5,mice
R8973 T13139 T13142 nummod −,mice
R8974 T13140 T13142 nmod /,mice
R8976 T13141 T13142 compound −,mice
R8977 T13142 T13137 pobj mice,in
R8978 T13143 T13123 punct .,showed
R8994 T13045 T13046 poss Our,data
R8995 T13046 T13048 nsubj data,show
R8996 T13047 T13048 advmod thus,show
R8997 T13048 T13048 ROOT show,show
R8998 T13049 T13051 amod significant,implications
R8999 T13050 T13051 amod clinical,implications
R9000 T13051 T13048 dobj implications,show
R9001 T13052 T13051 prep of,implications
R9002 T13053 T13052 pobj CCR5,of
R9003 T13054 T13048 punct ",",show
R9004 T13055 T13057 mark because,is
R9005 T13056 T13057 nsubj CCR5,is
R9006 T13057 T13048 advcl is,show
R9007 T13058 T13060 det a,protein
R9008 T13059 T13060 compound G,protein
R9009 T13060 T13057 attr protein,is
R9010 T13061 T13060 acl coupled,protein
R9011 T13062 T13061 dobj receptor,coupled
R9012 T13063 T13057 cc and,is
R9013 T13064 T13065 nsubj it,is
R9014 T13065 T13057 conj is,is
R9015 T13066 T13065 acomp amenable,is
R9016 T13067 T13068 aux to,use
R9017 T13068 T13066 xcomp use,amenable
R9018 T13069 T13068 prep as,use
R9019 T13070 T13072 det a,molecule
R9020 T13071 T13072 amod small,molecule
R9021 T13072 T13069 pobj molecule,as
R9022 T13073 T13072 prep for,molecule
R9023 T13074 T13075 det the,inhibition
R9024 T13075 T13073 pobj inhibition,for
R9025 T13076 T13075 prep of,inhibition
R9026 T13077 T13076 pobj CCR5,of
R9027 T13078 T13048 punct .,show
R9028 T13079 T13081 amod Several,compounds
R9029 T13080 T13081 amod such,compounds
R9030 T13081 T13085 nsubj compounds,shown
R9031 T13082 T13085 aux have,shown
R9032 T13083 T13085 advmod already,shown
R9033 T13084 T13085 auxpass been,shown

bionlp-st-ge-2016-test-tees

Id Subject Object Predicate Lexical cue
T11346 479-485 Protein denotes IL-1Ra
T11345 473-478 Protein denotes NF-κB
T11344 161-171 Negative_regulation denotes inhibition
T11343 175-179 Protein denotes CCR5
T11342 80-106 Protein denotes G protein–coupled receptor
T11341 70-74 Protein denotes CCR5
R7460 T11343 T11344 themeOf CCR5,inhibition